GIT1

Across TCGA pan-cancer cohorts, GIT1 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated GIT1 data layer compared with 27 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher GIT1 Mutation is associated with better overall survival. In most high-consensus cancer types, elevated GIT1 expression acts as an unfavorable survival marker, although some lineages such as BLCA show a favorable association.

BLCA, KICH, and LGG are the cancer types where GIT1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	II,III,IV	1.000	0.407	.022	16	view →
KICH	DFS	Median	All	0.102	0.848	.004	13	view →
LGG	DFS	Median	All	0.192	0.738	.005	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

GIT1–BLCA (OS)

Open the BLCA breakdown →